Validity of Sentinel Lymphnode Biopsy After Neoadjuvant Chemotherapy Cancer Patients With Radiologically Positive Axillary Lymph Nodes (VSNBNAC)

Yonsei University Health System (YUHS)

Status: Completed

Conditions: Breast Cancer

Treatments: Procedure: positron emission tomography and ultrasonogram; Procedure: complete axillary lymph node dissection; Drug: Neoadjuvant chemotherapy; Procedure: Sentinel lymph node biopsy

Study type: Observational

Funder types: Other

Identifiers

NCT01622478

GNSBCC001

Details and patient eligibility

About

Sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC) is currently debatable. It is possible that the tumor response to chemotherapy may alter the lymphatic drainage thus causing lower SLN identification rate and higher false negative rate. Further, the response of NAC can be different in each lymph nodes. It is doubtful whether SLNB can accurately predict axillary lymph node (ALN) status after NAC. The aim of this study to determine the identification rate, the false-negative rate, and the accuracy of SLNB after NAC for node positive breast cancer.

Enrollment: 120 patients

Sex: Female

Ages: 20 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Advanced breast cancer patients with node-positive proved in preoperative imaging study
• ECOG status 0-1

Exclusion criteria

• No previous cancer history
• No previous chemotherapy history

Trial design

120 participants in 1 patient group

Clinically node-positive patients before NAC

Description:

Patients with clinically positive lymph node receiving neoadjuvant chemotherapy 1. Clinically negative-node after NAC 2. Clinically positive-node after NAC

Treatment:

Procedure: positron emission tomography and ultrasonogram

Procedure: Sentinel lymph node biopsy

Procedure: complete axillary lymph node dissection

Drug: Neoadjuvant chemotherapy